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Purpose of the study
Currently there is an effort to develop simple, more
convenient antiretroviral regimens for children to reduce
costs and promote adherence. We report the plasma
pharmacokinetics (PK) of lamivudine (3TC), abacavir
(ABC) and zidovudine (ZDV) taken twice daily as syrups
versus scored tablets in HIV-1 infected Ugandan
children.
Methods
Eligible children from 2 Ugandan centres in the
ARROW trial, weighing 12-15kg, had taken ZDV, 3TC
and ABC syrups twice daily for at least 24 weeks, and
were ready to switch from syrups to scored tablets. Chil-
dren were expected to remain in the 12-15kg weight
band (i.e. same dosing band) for the next 4 weeks.
Those with illnesses affecting PK (e.g., severe diarrhea,
vomiting) were ineligible; children who missed any dose
in the 3 days before sampling were excluded. Blood
samples were collected at 0, 1, 2, 4, 6, 8 and 12 hours
after the child’s last morning dose on syrups prior to
switching to scored tablets of Combivir (ZDV+3TC) and
ABC, and then repeated 4 weeks later. Adjusted Geo-
metric Mean Ratios (aGMR) were calculated to compare
plasma area under the curve (AUC0-12) and peak con-
centrations (Cmax) between tablets versus syrup.
Results
19 eligible children (6 boys) were enrolled with median
age of 3 (range 1.8-4) years. Following WHO tables,
actual doses increased by 25% as children switched from
syrups to scored tablets within the 12-15kg weight-band,
and so PK parameters were normalised to the tablet
dose. For ZDV and ABC, dose-normalised tablet AUC0-
12 and Cmax were equivalent to syrup, but dose-
normalised 3TC exposure was ~55% higher on tablets.
Actual 3TC exposure on 75mg tablet dose (AUC0-12
(%CV) 8.2 (20%) h.mg/L) was higher than expected
compared to previous paediatric studies, and lower than
expected for 60mg syrup dose (4.2 (36%) h.mg/L). There
was no evidence of dosing or bioanalytical errors, or
problems with administration (vomiting), or with integ-
rity of the product batches, such as degradation.
Conclusions
Although ZDV and ABC syrups and tablets gave equiva-
lent exposures, we found higher plasma exposure from
twice daily 3TC scored tablets compared to syrups.
Further studies to understand the underlying mechan-
ism for differing 3TC exposures from solution and
tablets in the target population of HIV-infected children
are needed.
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